Sanofi's Iniparib Fails Phase III Study, but Firm Investigating Benefit by Molecular Subtypes
June 15, 2011
Sanofi's Iniparib Fails Phase III Study, but Firm Investigating Benefit by Molecular Subtypes
"[Biomarker] analyses are underway to evaluate iniparib benefit within the intrinsic subtypes, as well as within other molecularly defined subpopulations," a study investigator said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Missed Opportunity: Would PGx Have Helped Sanofi-Aventis Avoid Phase III Failure for Iniparib?
February 2, 2011 / Pharmacogenomics Reporter - MDxHealth Nets Methylation Biomarker Deal with Pfizer, Partners for PARP Inhibitor
February 2, 2011 / Pharmacogenomics Reporter - Myriad Details Companion Dx Strategy for PARP, PTEN Inhibitors at Goldman Sachs Conference
June 30, 2010 / Pharmacogenomics Reporter - FDA Official Says Personalized Medicine Regulation Taking Shape Following Zelboraf, Xalkori Success
February 1, 2012 / Pharmacogenomics Reporter - Pfizer, Abbott Ink Deal to Develop Companion Dx for PGx-based NSCLC Drug
September 2, 2009 / Pharmacogenomics Reporter